Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | FDA approves Imbruvica to treat rare form of non-Hodgkin lymphomaBy: NAPSRx Approval of Imbruvica for WM was based on a clinical study involving 63 participants who received 420 milligram dose of the medication until disease progression or side effects became intolerable. According to the results, 62 percent of the participants had their cancer shrink after treatment. Waldenström’ Imbruvica is already approved for use in patients with cell lymphoma who received one prior therapy, patients with previously treated chronic lymphocytic leukemia (CLL) and for CLL patients who carry a deletion in chromosome 17. The approved use for Waldenström’ CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES! With such industry leaders paving the way with new, beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to sell their product both proficiently and efficiently. The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community. Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives( End
Account Email Address Account Phone Number Disclaimer Report Abuse
|